The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Abstract
Avoidance of apoptosis is critical for the development and sustained growth of tumours. The pro-survival protein myeloid cell leukemia 1 (MCL1) is overexpressed in many cancers, but the development of small molecules targeting this protein that are amenable for clinical testing has been challenging. Here we describe S63845, a small molecule that specifically binds with high affinity to the BH3-binding groove of MCL1. Our mechanistic studies demonstrate that S63845 potently kills MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway. In vivo, S63845 shows potent anti-tumour activity with an acceptable safety margin as a single agent in several cancers. Moreover, MCL1 inhibition, either alone or in combination with other anti-cancer drugs, proved effective against several solid cancer-derived cell lines. These results point towards MCL1 as a target for the treatment of a wide range of tumours.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prior studies have demonstrated that sensitivity of cancer cells to MCL-1 inhibition is inversely related to BCL-XL expression level and the capacity for BCL-XL to neutralize pro-apoptotic BH3 proteins such as BIM60,61.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [60]
In the citing paper
“Conversely, the BCL2 inhibitor venetoclax is currently available for the treatment of CLL patients who fail to obtain clinical benefit from conventional therapies [1046], and several other molecules with a similar mechanism of action are currently in clinical development [118] (source https://clinicaltrials.gov/).”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [118]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,796
MOLREP : an Automated Program for Molecular Replacement
Vagin, A. A., & Teplyakov, A. (1997) · Journal of Applied Crystallography · doi:10.1107/s0021889897006766 · Cited by 4,756
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219
Self-citationABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Self-citationTargeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,930
Self-citationChen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816
Self-citation
Cited by
Sorted by citations
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,520
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El‐Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,676
BCL-2 family proteins: changing partners in the dance towards death
Kale, J., Osterlund, E. J., & Andrews, D. W. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.186 · Cited by 1,574
BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis
McArthur, K., Whitehead, L. W., Heddleston, J. M., Li, L., Padman, B. S., Oorschot, V., Geoghegan, N. D., Chappaz, S., Davidson, S., San Chin, H., et al. (2018) · Science · doi:10.1126/science.aao6047 · Cited by 1,072
Emerging connectivity of programmed cell death pathways and its physiological implications
Bedoui, S., Herold, M. J., & Strasser, A. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0270-8 · Cited by 1,027
Self-citationDrugging the ‘undruggable’ cancer targets
Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.36 · Cited by 927
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Ashkenazi, A., Fairbrother, W. J., Leverson, J. D., & Souers, A. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.253 · Cited by 903
Mechanisms of BCL-2 family proteins in mitochondrial apoptosis
Czabotar, P. E., & García‐Sáez, A. J. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00629-4 · Cited by 739
BCL-2 family isoforms in apoptosis and cancer
Warren, C., Wong‐Brown, M. W., & Bowden, N. A. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1407-6 · Cited by 717
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0668-z · Cited by 688
Mitochondrial inner membrane permeabilisation enables mtDNA release during apoptosis
Riley, J. S., Quarato, G., Cloix, C., Lopez, J., O'Prey, J., Pearson, M., Chapman, J., Sesaki, H., Carlin, L. M., Passos, J. F., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201899238 · Cited by 551
Targeting BCL-2 regulated apoptosis in cancer
Campbell, K. J., & Tait, S. W. G. (2018) · Open Biology · doi:10.1098/rsob.180002 · Cited by 564
The BCL-2 arbiters of apoptosis and their growing role as cancer targets
Adams, J. M., & Cory, S. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.161 · Cited by 530
BCL-2 protein family: attractive targets for cancer therapy
Kaloni, D., Diepstraten, S. T., Strasser, A., & Kelly, G. L. (2022) · APOPTOSIS · doi:10.1007/s10495-022-01780-7 · Cited by 547
Self-citationMechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2
Klemm, T., Ebert, G., Calleja, D. J., Allison, C. C., Richardson, L. W., Bernardini, J. P., Lu, B. G. C., Kuchel, N. W., Grohmann, C., Shibata, Y., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2020106275 · Cited by 508
Tron, A. E., Belmonte, M. A., Adam, A., Aquila, B. M., Boise, L., Chiarparin, E., Cidado, J. R., Embrey, K. J., Gangl, E. T., Gibbons, F. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07551-w · Cited by 498
The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
Vogler, M., Braun, Y., Smith, V. M., Westhoff, M.-A., Pereira, R. S., Pieper, N. M., Anders, M., Callens, M., Vervliet, T., Abbas, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02176-0 · Cited by 462
Caenepeel, S., Brown, S. P., Belmontes, B., Moody, G., Keegan, K. S., Chui, D., Whittington, D. A., Huang, X., Poppe, L., Cheng, A. C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0387 · Cited by 432
Self-citationExtrinsic and intrinsic apoptosis activate pannexin‐1 to drive NLRP3 inflammasome assembly
Chen, K. W., Demarco, B., Heilig, R., Shkarina, K., Boettcher, A., Farady, C. J., Pelczar, P., & Brož, P. (2019) · The EMBO Journal · doi:10.15252/embj.2019101638 · Cited by 397
Ramsey, H. E., Fischer, M. A., Lee, T., Gorska, A. E., Arrate, M. P., Fuller, L., Boyd, K. L., Strickland, S. A., Sensintaffar, J., Hogdal, L. J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0140 · Cited by 385
The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells
Nechiporuk, T., Kurtz, S. E., Nikolova, O. H., Liu, T., Jones, C. L., D’Alessandro, A., Culp‐Hill, R., d’Almeida, A., Joshi, S. K., Rosenberg, M. W., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0125 · Cited by 392
Snyder, A. G., Hubbard, N., Messmer, M. N., Kofman, S. B., Hagan, C. E., Orozco, S. L., Chiang, K., Daniels, B. P., Baker, D. A., & Oberst, A. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw2004 · Cited by 382
Cell Death in the Origin and Treatment of Cancer
Strasser, A., & Vaux, D. L. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.014 · Cited by 377
Self-citationAdvances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
Short, N. J., Konopleva, M. Y., Kadia, T. M., Borthakur, G. M., Ravandi, F., Dinardo, C. D., & Daver, N. G. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1011 · Cited by 382
Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality
Ishizawa, J., Zarabi, S. F., Davis, R. E., Halgas, O., Nii, T., Jitkova, Y., Zhao, R., St‐Germain, J. R., Heese, L. E., Egan, G., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.014 · Cited by 380
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
Guièze, R., Liu, V. M., Rosebrock, D., Jourdain, A. A., Hernández-Sánchez, M., Martinez Zurita, A., Sun, J., Ten Hacken, E., Baranowski, K., Thompson, P. A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.005 · Cited by 361
Apoptotic cell death in disease—Current understanding of the NCCD 2023
Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 352
Anti-apoptotic BCL-2 family members in development
Opferman, J. T., & Kothari, A. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.170 · Cited by 349
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs
Diepstraten, S. T., Anderson, M. A., Czabotar, P. E., Lessène, G., Strasser, A., & Kelly, G. L. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00407-4 · Cited by 351
Self-citationTargeting an RNA-Binding Protein Network in Acute Myeloid Leukemia
Wang, E., Lu, S. X., Pastore, A., Chen, X., Imig, J., Chun-Wei Lee, S., Hockemeyer, K., Ghebrechristos, Y. E., Yoshimi, A., Inoue, D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.010 · Cited by 338
Cell death pathways: intricate connections and disease implications
Kist, M., & Vucic, D. (2021) · The EMBO Journal · doi:10.15252/embj.2020106700 · Cited by 337
Why do BCL-2 inhibitors work and where should we use them in the clinic?
Montero, J., & Letai, A. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.183 · Cited by 335
Massively parallel assessment of human variants with base editor screens
Hanna, R. E., Hegde, M., Fagre, C. R., DeWeirdt, P. C., Sangree, A. K., Szegletes, Z., Griffith, A., Feeley, M. N., Sanson, K. R., Baidi, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.012 · Cited by 316
Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells
Stevens, B. M., Jones, C. L., Pollyea, D. A., Culp‐Hill, R., D’Alessandro, A., Winters, A. C., Krug, A., Abbott, D., Goosman, M., Pei, S., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00126-z · Cited by 312
Targeting MCL-1 in cancer: current status and perspectives
Wang, H., Guo, M., Wei, H., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01079-1 · Cited by 318
Pathways and mechanisms of venetoclax resistance
Bose, P., Gandhi, V. V., & Konopleva, M. Y. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1283032 · Cited by 311
Cidado, J. R., Boiko, S., Proia, T. A., Ferguson, D., Criscione, S. W., Martin, M. S., Pop-Damkov, P., Su, N., Franklin, V. N. R., Chilamakuri, C. S. R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1853 · Cited by 294
BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
Mérino, D., Kelly, G. L., Lessène, G., Wei, A. H., Roberts, A. W., & Strasser, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.004 · Cited by 300
Self-citationOrthologous CRISPR–Cas9 enzymes for combinatorial genetic screens
Najm, F. J., Strand, C., Donovan, K. F., Hegde, M., Sanson, K. R., Vaimberg, E. W., Sullender, M. E., Hartenian, E., Kalani, Z., Fusi, N., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4048 · Cited by 279
Moreau, P., Chanan-Khan, A. A., Roberts, A. W., Agarwal, A. B., Facon, T. T. F., Kumar, S. K., Touzeau, C., Punnoose, E. A., Cordero, J., Munasinghe, W. P., et al. (2017) · Blood · doi:10.1182/blood-2017-06-788323 · Cited by 273
Self-citationSublethal cytochrome c release generates drug-tolerant persister cells
Kalkavan, H., Chen, J., Crawford, J. C., Quarato, G., FITZGERALD, P. J., Tait, S. W. G., Goding, C. R., & Green, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.07.025 · Cited by 271
Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance
Kapoor, I., Bodo, J., Hill, B. T., Hsi, E. D., & Almasan, A. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03144-y · Cited by 255
Vince, J. E., Nardo, D. D., Gao, W., Vince, A. J., Hall, C. M., McArthur, K., Simpson, D. S., Vijayaraj, S. L., Lindqvist, L., Bouillet, P., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.103 · Cited by 236
Self-citationLiao, Y., Zhao, J., Bulek, K., Tang, F., Chen, X., Cai, G., Jia, S., Fox, P. L., Huang, E. H., Pizarro, T. T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14698-y · Cited by 233
Self-citationThe BCL-2 family of proteins and mitochondrial outer membrane permeabilisation
Birkinshaw, R. W., & Czabotar, P. E. (2017) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2017.04.001 · Cited by 229
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
Carter, J. L., Hege-Hurrish, K., Yang, J., Kalpage, H. A., Su, Y., Edwards, H. J., Hüttemann, M., Taub, J. W., & Ge, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00361-x · Cited by 230
Targeting MCL-1 in hematologic malignancies: Rationale and progress
Wei, A. H., Roberts, A. W., Spencer, A. G., Rosenberg, A. S., Siegel, D. S. D., Walter, R. B., Caenepeel, S. R., Hughes, P. E., McIver, Z., Mezzi, K., et al. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100672 · Cited by 212
Self-citationMCL-1 is a prognostic indicator and drug target in breast cancer
Campbell, K. J., Dhayade, S., Ferrari, N., Sims, A. H., Johnson, E. R., Mason, S. M., Dickson, A., Ryan, K. M., Kalna, G., Edwards, J., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0035-2 · Cited by 203
BCL2 and MCL1 inhibitors for hematologic malignancies
Roberts, A. W., Wei, A. H., & Huang, D. C. S. (2021) · Blood · doi:10.1182/blood.2020006785 · Cited by 211
Self-citationCo-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer
López, A., Reyna, D. E., Gitego, N., Kopp, F., Zhou, H., Miranda-Román, M. A., Nordstrøm, L. U., Narayanagari, S.-R., Chi, P., Vilar, E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28741-7 · Cited by 203
Zhang, Q., Riley-Gillis, B. M., Han, L., Jia, Y., Lodi, A., Zhang, H., Ganesan, S., Pan, R. A., Konoplev, S. N., Sweeney, S., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00870-3 · Cited by 202
Apoptosis in Cancer Biology and Therapy
Moyer, A. F., Tanaka, K., & Cheng, E. H. Y. (2025) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-115023 · Cited by 212
VDAC2 enables BAX to mediate apoptosis and limit tumor development
Chin, H. S., Li, M. X., Tan, I. K. L., Ninnis, R. L., Reljic, B., Scicluna, K., Dagley, L. F., Sandow, J. J., Kelly, G. L., Samson, A. L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07309-4 · Cited by 196
Self-citationBCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
Lee, E. F., Harris, T. J., Tran, S. H., Evangelista, M., Arulananda, S., John, T., Ramnac, C., Hobbs, C., Zhu, H., Gunasingh, G. P., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1568-3 · Cited by 188
Self-citationReduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Bhatt, S., Pioso, M. S., Olesinski, E. A., Yilma, B., Ryan, J. A., Mashaka, T., Buon, L., Adamia, S., Zhu, H., Kuang, Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.10.010 · Cited by 194
Mérino, D., Whittle, J. R., Vaillant, F., Serrano, A., Gong, J.-N., Giner, G., Maragno, A. L., Chanrion, M., Schneider, E., Pal, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7049 · Cited by 195
Self-citationEmerging molecular therapeutic targets for cholangiocarcinoma
Ilyas, S. I., & Gores, G. J. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.026 · Cited by 180
Moujalled, D. M., Pomilio, G., Ghiurau, C., Ivey, A., Salmon, J. M., Rijal, S., MacRaild, S., Zhang, L., Teh, T., Tiong, I. S., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0261-3 · Cited by 171
Self-citationMCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
Bolomsky, A., Vogler, M., Köse, M. C., Heckman, C. A., Ehx, G., Ludwig, H., & Caers, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01007-9 · Cited by 178
Basu, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107943 · Cited by 171
Control of cell death and mitochondrial fission by ERK 1/2 MAP kinase signalling
Cook, S. J., Stuart, K., Gilley, R., & Sale, M. J. (2017) · FEBS Journal · doi:10.1111/febs.14122 · Cited by 176
Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance
Shahar, N., & Larisch, S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100712 · Cited by 175
Knight, T. E., Luedtke, D. A., Edwards, H. J., Taub, J. W., & Ge, Y. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.01.015 · Cited by 170
Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
Barwick, B. G., Gupta, V. A., Vertino, P. M., & Boise, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01121 · Cited by 184
Baltschukat, S., Engstler, B. S., Huang, A., Hao, H.-X., Tam, A., Wang, H. Q., Liang, J., DiMare, M. T., Bhang, H.-E. C., Wang, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2814 · Cited by 167
The multiple mechanisms of MCL1 in the regulation of cell fate
Widden, H., & Placzek, W. J. (2021) · Communications Biology · doi:10.1038/s42003-021-02564-6 · Cited by 162
Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia
Reyna, D. E., Garner, T. P., López, A., Kopp, F., Choudhary, G. S., Sridharan, A., Narayanagari, S.-R., Mitchell, K., Dong, B., Bartholdy, B., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.001 · Cited by 164
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
Teh, T.-C., Nguyen, N.-Y., Moujalled, D. M., Segal, D., Pomilio, G., Rijal, S., Jabbour, A. M., Cummins, K. D., Lackovic, K., Blombery, P. A., et al. (2017) · Leukemia · doi:10.1038/leu.2017.243 · Cited by 164
Self-citationThe rise of apoptosis: targeting apoptosis in hematologic malignancies
Valentin, R., Grabow, S., & Davids, M. S. (2018) · Blood · doi:10.1182/blood-2018-02-791350 · Cited by 163
New directions for emerging therapies in acute myeloid leukemia: the next chapter
Daver, N., Wei, A. H., Pollyea, D. A., Fathi, A. T., Vyas, P., & DiNardo, C. D. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00376-1 · Cited by 159
Self-citationDevelopment of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
Lv, D., Pal, P., Liu, X., Jia, Y., Thummuri, D., Zhang, P., Hu, W., Pei, J., Zhang, Q., Zhou, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27210-x · Cited by 158
Carrington, E. M., Zhan, Y., Brady, J. L., Zhang, J., Sutherland, R. M., Anstee, N. S., Schenk, R. L., Vikstrom, I. B., Delconte, R. B., Segal, D., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.30 · Cited by 157
Self-citationMCL-1 inhibition in cancer treatment
Xiang, W., Yang, C., & Bai, L. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s146228 · Cited by 159
Alimbetov, D. S., Askarova, S., Umbayev, B. A., Davis, T., & Kipling, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061690 · Cited by 159
Minzel, W., Venkatachalam, A., Fink, A., Hung, E., Brachya, G., Burstain, I., Shaham, M., Rivlin, A., Omer, I., Zinger, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.045 · Cited by 161
Chromosome 1q21 abnormalities in multiple myeloma
Schmidt, T. M., Fonseca, R., & Usmani, S. Z. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00474-8 · Cited by 154
A first-generation pediatric cancer dependency map
Dharia, N. V., Kugener, G., Guenther, L. M., Malone, C. F., Durbin, A. D., Hong, A. L., Howard, T. P., Bandopadhayay, P., Wechsler, C. S., Fung, I., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00819-w · Cited by 153
Roberts, A. W., & Huang, D. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.553 · Cited by 153
Self-citationRational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions
Wang, X., Ni, D., Liu, Y., & Lu, S. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.682675 · Cited by 162
D’Aguanno, S., & Bufalo, D. D. (2020) · Cells · doi:10.3390/cells9051287 · Cited by 158
Quercetin modulates signaling pathways and induces apoptosis in cervical cancer cells
Sundaram, M. K., Raina, R., Afroze, N., Bajbouj, K., Hamad, M. A., Haque, S., & Hussain, A. (2019) · Bioscience Reports · doi:10.1042/bsr20190720 · Cited by 150
Recent advances in the development of Mcl-1 inhibitors for cancer therapy
Hird, A. W., & Tron, A. E. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.007 · Cited by 150
Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors
Zhang, S., Zhang, M., Jing, Y., Yin, X., Ma, P., Zhang, Z., Wang, X., Di, W. J., & Zhuang, G. (2018) · Nature Communications · doi:10.1038/s41467-017-02693-9 · Cited by 150
Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells
Tong, J., Wang, P., Tan, S., Chen, D., Nikolovska‐Coleska, Z., Zou, F., Yu, J., & Zhang, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3242 · Cited by 143
BH3-only proteins target BCL-xL/MCL-1, not BAX/BAK, to initiate apoptosis
Huang, K., O’Neill, K. L., Li, J., Zhou, W., Han, N., Pang, X., Wu, W., Struble, L. R., Borgstahl, G., Liu, Z., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0231-y · Cited by 145
Mali, R. S., Zhang, Q., DeFilippis, R., Cavazos, A., Kuruvilla, V. M., Raman, J., Mody, V., Choo, E. F., Dail, M., Shah, N. P., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.244020 · Cited by 140
Targeting Bcl-2 for the treatment of multiple myeloma
Touzeau, C., Maciag, P., Amiot, M., & Moreau, P. (2018) · Leukemia · doi:10.1038/s41375-018-0223-9 · Cited by 142
Thijssen, R., Diepstraten, S. T., Moujalled, D. M., Chew, E., Flensburg, C., Shi, M. X., Dengler, M. A., Litalien, V., MacRaild, S., Chen, M., et al. (2021) · Blood · doi:10.1182/blood.2020010167 · Cited by 135
Self-citationGenetic screens in isogenic mammalian cell lines without single cell cloning
DeWeirdt, P. C., Sangree, A. K., Hanna, R. E., Sanson, K. R., Hegde, M., Strand, C., Persky, N. S., & Doench, J. G. (2020) · Nature Communications · doi:10.1038/s41467-020-14620-6 · Cited by 138
Li, Z., He, S., & Look, A. T. (2018) · Leukemia · doi:10.1038/s41375-018-0201-2 · Cited by 132
BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy
Ramesh, P., & Medema, J. P. (2020) · APOPTOSIS · doi:10.1007/s10495-020-01601-9 · Cited by 134
Shahbandi, A., Rao, S. G., Anderson, A. Y., Frey, W. D., Olayiwola, J. O., Ungerleider, N., & Jackson, J. G. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0564-6 · Cited by 135
Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer
Troiani, M., Colucci, M., D’Ambrosio, M., Guccini, I., Pasquini, E., Varesi, A., Valdata, A., Mosole, S., Revandkar, A., Attanasio, G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29824-1 · Cited by 134
Thomalla, D., Beckmann, L., Grimm, C., Oliverio, M., Meder, L., Herling, C., Nieper, P., Feldmann, T., Merkel, O., Lorsy, E., et al. (2022) · Blood · doi:10.1182/blood.2021014304 · Cited by 128
Understanding cell cycle and cell death regulation provides novel weapons against human diseases
Wiman, K. G., & Zhivotovsky, B. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12609 · Cited by 133
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML
Wei, A. H., & Tiong, I. S. (2017) · Blood · doi:10.1182/blood-2017-08-784066 · Cited by 129
Self-citationOne-Pot Synthesis of Novel Thiazoles as Potential Anti-Cancer Agents
Sayed, A. R., Gomha, S. M., Taher, E. A., Muhammad, Z. A., El-Seedi, H. R., Gaber, H. M., & Ahmed, M. M. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s221263 · Cited by 127
Leverson, J. D., Sampath, D., Souers, A. J., Rosenberg, S. H., Fairbrother, W. J., Amiot, M., Konopleva, M. Y., & Letai, A. G. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0797 · Cited by 126
Carter, B. Z., Mak, P. Y., Tao, W., Warmoes, M. O., Lorenzi, P. L., Mak, D. H. F., Ruvolo, V. R., Tan, L., Cidado, J. R., Drew, L., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.260331 · Cited by 126
Metadata
- Authors
- Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., Bruno, A., Csekei, M., Paczal, A., Szabo, Z. B., Sipos, S., Radics, G., Proszenyak, A., Balint, B., Ondi, L., Blasko, G., Robertson, A., Surgenor, A., Dokurno, P., Chen, I., Matassova, N., Smith, J., Pedder, C., Graham, C., Studeny, A., Lysiak-Auvity, G., Girard, A.-M., Gravé, F., Segal, D., Riffkin, C. D., Pomilio, G., Galbraith, L. C. A., Aubrey, B. J., Brennan, M. S., Herold, M. J., Chang, C., Guasconi, G., Cauquil, N., Melchiore, F., Guigal-Stephan, N., Lockhart, B., Colland, F., Hickman, J. A., Roberts, A. W., Huang, D. C. S., Wei, A. H., Strasser, A., Lessene, G., & Geneste, O.
- Affiliations
- Vernalis (R&D) Limited (United Kingdom) (GB)
- Institut de Recherches Internationales Servier (France) (FR)
- The University of Melbourne (AU)
- Monash University (AU)
- The Royal Melbourne Hospital (AU)
- The Alfred Hospital (AU)
- Corresponding author
- Geneste, Olivier
- ORCID
- Kotschy, András
- Murray, James
- Davidson, James
- Kelly, Gemma L.
- Moujalled, Donia M.
- Surgenor, Allan
- Dokurno, Pawel
- Chen, Ijen
- Matassova, Natalia
- Graham, Christopher
- Girard, Anne-Marie
- Segal, David
- Riffkin, Chris D.
- Galbraith, Laura C. A.
- Aubrey, Brandon J.
- Brennan, Margs S.
- Herold, Marco J.
- Chang, Catherine
- Melchiore, Fabien
- Colland, Frédéric
- Hickman, John A.
- Roberts, Andrew W.
- Huang, David C. S.
- Wei, Andrew H.
- Strasser, Andreas
- Venue
- Nature
- Published
- 2016-10
- Volume
- 538
- Issue
- 7626
- Pages
- 477-482
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2534349779
- Semantic Scholar
- 804d41f048a7386a3e6b3fcd1589511de3fabcd4
- Cited by
- 1,047
- References
- 52
- Citations by year
- 2026: 63 · 2025: 87 · 2024: 75 · 2023: 100 · 2022: 99 · 2021: 133 · 2020: 152 · 2019: 123 · 2018: 120 · 2017: 83 · 2016: 8
- FWCI
- 48.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- S63845, BH3-binding groove, apoptosis, mitochondrial apoptosis, multiple myeloma, leukemia, lymphoma, solid tumors, antitumour activity, drug safety, combination therapy
- MeSH terms
- Animals, Antineoplastic Agents, Female, Humans, Leukemia, Lymphoma, Male, Models, Biological, Models, Molecular, Multiple Myeloma, Neoplasms, Pyrimidines, Thiophenes, Apoptosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, bcl-2 Homologous Antagonist-Killer Protein, bcl-2-Associated X Protein, Mice, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
